Bicycle Therapeutics to Host R&D Day on December 14
November 30 2023 - 6:00AM
Business Wire
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company
pioneering a new and differentiated class of therapeutics based on
its proprietary bicyclic peptide (Bicycle®) technology, today
announced that the company will host its first Research and
Development (R&D) Day on Thursday, December 14. The event will
take place in New York City from 8 a.m. to 12 p.m. Eastern Time and
will be simultaneously webcast.
Bicycle Therapeutics executives will provide investors and
analysts with an overview of the company’s R&D strategy and
pipeline opportunities, with an emphasis on clinical updates for
BT8009, BT5528 and BT7480. The company will also highlight the
broad capabilities of its novel Bicycle® platform technology.
Analysts and investors who are interested in attending in person
should contact bicycle@argotpartners.com. A live webcast of the
R&D Day will be accessible from the Investor section of the
company’s website, www.bicycletherapeutics.com. A replay of the
webcast will be archived and available following the event.
About Bicycle Therapeutics Bicycle Therapeutics is
a clinical-stage biopharmaceutical company developing a novel class
of medicines, referred to as Bicycles, for diseases that are
underserved by existing therapeutics. Bicycles are fully synthetic
short peptides constrained with small molecule scaffolds to form
two loops that stabilize their structural geometry. This constraint
facilitates target binding with high affinity and selectivity,
making Bicycles attractive candidates for drug development. The
company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC™)
targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC
targeting EphA2; and BT7480, a Bicycle TICA™ targeting Nectin-4 and
agonizing CD137, in company-sponsored Phase 1/2 trials. In
addition, BT1718, a BTC that targets MT1-MMP, is being investigated
in a Phase 1/2a clinical trial sponsored by the Cancer Research UK
Centre for Drug Development. Bicycle Therapeutics is headquartered
in Cambridge, UK, with many key functions and members of its
leadership team located in Cambridge, Mass. For more information,
visit bicycletherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231130298942/en/
Investors: Stephanie Yao SVP, Investor Relations and
Corporate Communications ir@bicycletx.com 857-523-8544
Media: Argot Partners Sarah Sutton media@bicycletx.com
212-600-1902
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From May 2024 to Jun 2024
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From Jun 2023 to Jun 2024